Page last updated: 2024-12-08

adenosine 3'-phosphate-5'-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

adenosine 3',5'-bismonophosphate : An adenosine bisphosphate having two monophosphate groups at the 3'- and 5'-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID159296
CHEMBL ID574817
CHEBI ID17985
SCHEMBL ID42104
MeSH IDM0056673

Synonyms (41)

Synonym
gtpl1718
adenosine-3'-5'-bisphosphate
CHEBI:17985 ,
adenosine 3',5'-bis(dihydrogen phosphate)
adenosine 3',5'-bismonophosphate
adenosine-3'-5'-diphosphate
a3p ,
3'-phosphoadenylate
1053-73-2
adenosine 3',5'-bisphosphate
C00054
phosphoadenosine phosphate
a3p5p
1HI4
3',5'-adp
3'-phosphoadenosine 5'-phosphate
DB01812
adenosine 3'-phosphate-5'-phosphate
adenosine 3',5'-diphosphate
1VKJ ,
1O0F
CHEMBL574817
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
3'-adenylic acid, 5'-(dihydrogen phosphate)
unii-c65f80d52u
c65f80d52u ,
SCHEMBL42104
3'-phosphoryl-amp
3',5'-diphosphoadenosine
{[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}phosphonic acid
3,5-adp
adenosine 3,5-bis
3,5-diphosphoadenosine
adenosine 3,5-bisphosphate
5-(dihydrogen phosphate) 3-adenylate
5-(dihydrogen phosphate)3'-adenylic acid
3-phosphoadenosine 5-phosphate
[5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid
Q2825485
((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate
DTXSID50909413

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the 19 patients studied, there were negative correlations between dosage or absorption and extent of O-methylation and of sulfation of L-DOPA or its metabolites."( L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Decker, PA; Dousa, MK; Muenter, MD; Offord, KP; Tyce, GM; Weinshilboum, RM, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
adenosine bisphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (30)

PathwayProteinsCompounds
Sulfate/Sulfite Metabolism620
Androgen and Estrogen Metabolism1230
Sphingolipid Metabolism2335
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Tamoxifen Action Pathway1027
Fabry Disease2335
Krabbe Disease2335
Sulfite Oxidase Deficiency620
Aromatase Deficiency1230
Tamoxifen Metabolism Pathway1027
Acetaminophen Metabolism Pathway3016
Cysteine Biosynthesis1329
Sulfur Metabolism2833
Sulfur Metabolism (Butanesulfonate)2834
Sulfur Metabolism (Propanesulfonate)2834
Sulfur Metabolism (Ethanesulfonate)2834
Sulfur Metabolism (Isethionate)2834
Sulfur Metabolism (Methanesulfonate)2834
Flavone and Flavonol Biosynthesis627
Estrone Metabolism1622
Proteoglycan biosynthesis011
11p11.2 copy number variation syndrome216
sulfate assimilation011
Biochemical pathways: part I0466
Tamoxifen metabolism013
Sulfation biotransformation reaction010
Glucuronidation014

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, EOSINOPHIL-DERIVED NEUROTOXINHomo sapiens (human)Ki32.000032.000062.666792.0000AID977610
Chain A, EOSINOPHIL-DERIVED NEUROTOXINHomo sapiens (human)Ki32.000032.000062.666792.0000AID977610
Chain A, EOSINOPHIL-DERIVED NEUROTOXINHomo sapiens (human)Ki32.000032.000062.666792.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki5.00001.200024.050082.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki5.00001.200024.050082.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki5.00001.200024.050082.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki5.00001.200024.050082.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki5.00001.200024.050082.0000AID977610
P2Y purinoceptor 1Meleagris gallopavo (turkey)IC50 (µMol)9.54504.19006.04258.4600AID150475; AID165239
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, heparan sulfate (glucosamine) 3-O-sulfotransferase 1Mus musculus (house mouse)Kd14.000014.000014.000014.0000AID977611
P2Y purinoceptor 1Meleagris gallopavo (turkey)EC50 (µMol)1.81000.00251.70498.0000AID150468; AID165236
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
phosphatidylcholine biosynthetic processCholine O-acetyltransferaseHomo sapiens (human)
neurotransmitter transportCholine O-acetyltransferaseHomo sapiens (human)
neuromuscular synaptic transmissionCholine O-acetyltransferaseHomo sapiens (human)
acetylcholine biosynthetic processCholine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
choline O-acetyltransferase activityCholine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusCholine O-acetyltransferaseHomo sapiens (human)
cytosolCholine O-acetyltransferaseHomo sapiens (human)
synapseCholine O-acetyltransferaseHomo sapiens (human)
cytoplasmCholine O-acetyltransferaseHomo sapiens (human)
neuron projectionCholine O-acetyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID150468Concentration at which 50% of the maximal effect (stimulation of PLC at P2Y1 receptor in the turkey erythrocyte membranes) is reached1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.
AID1074988Inhibition of human PPTase up to 125 uM by gel-based fluorescence assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
AID150475In vitro antagonist activity at P2Y1 receptor in turkey erythrocyte membranes.1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.
AID165243Antagonist activity at P2Y1 receptor measured as capacity to inhibit phospholipase C stimulation elicited by 10 nM 2-MeSATP1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.
AID165236Agonist activity at P2Y1 receptor measured as capacity to stimulate 50% phospholipase C in turkey erythrocyte membranes1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.
AID150479Antagonist activity for inhibition of PLC elicited by 10 nM 2-MeSADP at P2Y purinoceptor 1 in turkey erythrocyte membranes1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.
AID150477Agonist activity for stimulation of PLC at P2Y purinoceptor 1 in the turkey erythrocyte membranes.1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.
AID52123Compound was tested for inhibition of choline acetyltransferase isolated from squid head ganglia1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Interaction of aromatic dyes with the coenzyme A binding site of choline acetyltransferase.
AID165240Agonist activity at P2Y1 receptor measured as capacity to stimulate phospholipase C in turkey erythrocyte membranes1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.
AID440574Binding affinity to Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase assessed as S-sulfocysteine formation at pH 5.5 by single turnover method in absence of thioredoxin2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Identification of critical ligand binding determinants in Mycobacterium tuberculosis adenosine-5'-phosphosulfate reductase.
AID165239Antagonist activity at P2Y1 receptor measured as capacity to inhibit 50% of phospholipase C stimulation elicited by 10 nM 2-MeSATP1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004The Journal of biological chemistry, Jun-11, Volume: 279, Issue:24
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1.
AID1811Experimentally measured binding affinity data derived from PDB2004The Journal of biological chemistry, Jun-11, Volume: 279, Issue:24
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001The Journal of biological chemistry, May-04, Volume: 276, Issue:18
Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN). High resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2001The Journal of biological chemistry, May-04, Volume: 276, Issue:18
Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN). High resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003Protein science : a publication of the Protein Society, Nov, Volume: 12, Issue:11
High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2003Protein science : a publication of the Protein Society, Nov, Volume: 12, Issue:11
High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
AID1346309Human P2Y1 receptor (P2Y receptors)1996Molecular pharmacology, Nov, Volume: 50, Issue:5
Identification of competitive antagonists of the P2Y1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (3.96)18.7374
1990's16 (15.84)18.2507
2000's44 (43.56)29.6817
2010's34 (33.66)24.3611
2020's3 (2.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.51 (24.57)
Research Supply Index4.63 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other99 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]